How big is Celldex Therapeutics, Inc.?

As of Jun 18, Celldex Therapeutics, Inc. has a market capitalization of $1.33 billion, with net sales of $7.56 million and a net profit of -$178.85 million over the last four quarters.

As of Jun 18, Celldex Therapeutics, Inc. has a market capitalization of 1,331.87 million, categorizing it as a Small Cap company.<BR><BR>As of Jun 18, the sum of net sales for the latest four quarters is 7.56 million, while the sum of net profit for the same period is -178.85 million.<BR><BR>As of Dec 24, the reporting period shows shareholder's funds of 747.00 million and total assets of 792.34 million.

What does Celldex Therapeutics, Inc. do?

Celldex Therapeutics, Inc. is a biopharmaceutical company specializing in immunotherapy for cancer and other diseases, with a market cap of approximately $1.33 billion. As of March 2025, it reported net sales of $1 million and a net loss of $54 million.

Overview:<BR>Celldex Therapeutics, Inc. is a biopharmaceutical company focused on the development and commercialization of immunotherapy technologies for the treatment of cancer and other diseases, operating within the Pharmaceuticals & Biotechnology industry and categorized as a Small Cap.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 1 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -54 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 1,331.87 Million (Small Cap)<BR><BR>Key Metrics:<BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.95 <BR>Return on Equity: -25.44% <BR>Price to Book: 1.89<BR><BR>Contact Details:<BR>Address: 53 Frontage Rd Ste 220, HAMPTON NJ: 08827-4034 <BR>Tel: 1 908 2007500 <BR>Fax: 1 908 4541911 <BR>Website: http://www.celldextherapeutics.com

Should I buy, sell or hold Celldex Therapeutics, Inc.?

Who are in the management team of Celldex Therapeutics, Inc.?

As of March 2022, the management team of Celldex Therapeutics, Inc. includes Independent Chairman Ms. Karen Shoos, President and CEO Mr. Anthony Marucci, and Independent Directors Mr. Keith Brownlie, Mr. Herbert Conrad, Mr. James Marino, and Dr. Harry Penner. They are responsible for guiding the company's strategic decisions.

As of March 2022, the management team of Celldex Therapeutics, Inc. includes the following individuals:<BR><BR>- Ms. Karen Shoos, who serves as the Independent Chairman of the Board.<BR>- Mr. Anthony Marucci, who is the President, Chief Executive Officer, and a Director.<BR>- Mr. Keith Brownlie, serving as an Independent Director.<BR>- Mr. Herbert Conrad, also an Independent Director.<BR>- Mr. James Marino, another Independent Director.<BR>- Dr. Harry Penner, who is an Independent Director as well.<BR><BR>This team is responsible for guiding the company and making strategic decisions.

Is Celldex Therapeutics, Inc. overvalued or undervalued?

As of November 9, 2022, Celldex Therapeutics, Inc. is considered risky and overvalued due to negative financial ratios and a poor long-term stock performance, despite recent short-term gains.

As of 9 November 2022, the valuation grade for Celldex Therapeutics, Inc. moved from does not qualify to risky, indicating a shift in perception regarding its financial health. The company appears to be overvalued given its significant negative ratios, including a Price to Book Value of 2.02, an EV to EBITDA of -3.51, and a ROE of -25.44%. In comparison to peers, Celldex's EV to EBITDA ratio is notably worse than Hims & Hers Health, Inc. at 66.5314 and RadNet, Inc. at 26.0674, both of which are also categorized as risky.<BR><BR>The company's recent stock performance shows a mixed picture; while it outperformed the S&P 500 over the past week and month, it has significantly underperformed over the longer term, with a 1-year return of -38.06% compared to the S&P 500's 17.14%. This suggests that despite short-term gains, the overall valuation and long-term outlook for Celldex Therapeutics remain concerning.

Is Celldex Therapeutics, Inc. technically bullish or bearish?

As of October 3, 2025, Celldex Therapeutics, Inc. shows a bullish technical trend with strong weekly indicators, despite mixed monthly signals, and has outperformed the S&P 500 in the past month but underperformed over the past year.

As of 3 October 2025, the technical trend for Celldex Therapeutics, Inc. has changed from mildly bullish to bullish. The weekly MACD is bullish, and the monthly RSI indicates a bullish stance, supporting the overall positive outlook. Daily moving averages are also bullish, while the weekly KST is bullish, although the monthly KST is bearish. The Bollinger Bands show a mildly bullish trend weekly but are mildly bearish monthly, indicating some mixed signals. Dow Theory reflects a mildly bullish stance in both weekly and monthly assessments.<BR><BR>In terms of performance, the stock has returned 15.35% over the past month compared to the S&P 500's 4.15%, but it has underperformed over the longer term, with a 1-year return of -13.93% versus the S&P 500's 17.82%. Overall, the current technical stance is bullish with moderate strength.